Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
retinal vein occlusion
Manufacturing
Manufacturing issues cause FDA to delay decisions on Eylea HD
The FDA has extended its target action dates for two applications to expand the use of Eylea’s high-dose formulation.
Kevin Dunleavy
Aug 20, 2025 2:32pm
FDA denies Regeneron's bid for dosage flexibility on Eylea
Apr 21, 2025 8:45am
JPM25: Regeneron has few answers for declining sales of Eylea HD
Jan 14, 2025 10:25am
Eylea HD passes test in retinal vein occlusion, teeing up filing
Dec 18, 2024 8:20am
Roche's juggernaut Vabysmo routs analyst consensus
Apr 24, 2024 11:29am
Roche's Vabysmo snares FDA nod to treat retinal vein occlusion
Oct 27, 2023 11:07am
